The mixed Q4 financial results suggest that while some aspects of Alnylam Pharmaceuticals' financial performance may have met or exceeded expectations, others fell short. This discrepancy likely led to investor uncertainty and concern, resulting in a decrease in the company's stock price. Given the direct impact of earnings reports on stock prices, this news is highly relevant and important to investors, with a high level of confidence in the analysis.